Search Results - "Padda, Sukhmani K."

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline by Daly, Megan E, Singh, Navneet, Ismaila, Nofisat, Antonoff, Mara B, Arenberg, Douglas A, Bradley, Jeffrey, David, Elizabeth, Detterbeck, Frank, Früh, Martin, Gubens, Matthew A, Moore, Amy C, Padda, Sukhmani K, Patel, Jyoti D, Phillips, Tanyanika, Qin, Angel, Robinson, Clifford, Simone, 2nd, Charles B

“…To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). An Expert Panel…”
Get full text

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition by Nabet, Barzin Y., Esfahani, Mohammad S., Moding, Everett J., Hamilton, Emily G., Chabon, Jacob J., Rizvi, Hira, Steen, Chloe B., Chaudhuri, Aadel A., Liu, Chih Long, Hui, Angela B., Almanza, Diego, Stehr, Henning, Gojenola, Linda, Bonilla, Rene F., Jin, Michael C., Jeon, Young-Jun, Tseng, Diane, Liu, Cailian, Merghoub, Taha, Neal, Joel W., Wakelee, Heather A., Padda, Sukhmani K., Ramchandran, Kavitha J., Das, Millie, Plodkowski, Andrew J., Yoo, Christopher, Chen, Emily L., Ko, Ryan B., Newman, Aaron M., Hellmann, Matthew D., Alizadeh, Ash A., Diehn, Maximilian

“…Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs) can produce remarkably durable responses, most patients…”
Get full text

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling by Chaudhuri, Aadel A, Chabon, Jacob J, Lovejoy, Alexander F, Newman, Aaron M, Stehr, Henning, Azad, Tej D, Khodadoust, Michael S, Esfahani, Mohammad Shahrokh, Liu, Chih Long, Zhou, Li, Scherer, Florian, Kurtz, David M, Say, Carmen, Carter, Justin N, Merriott, David J, Dudley, Jonathan C, Binkley, Michael S, Modlin, Leslie, Padda, Sukhmani K, Gensheimer, Michael F, West, Robert B, Shrager, Joseph B, Neal, Joel W, Wakelee, Heather A, Loo, Jr, Billy W, Alizadeh, Ash A, Diehn, Maximilian

“…Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant…”
Get more information

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach by Padda, Sukhmani K, Reckamp, Karen L

Get more information

Diffuse high intensity PD-L1 staining in thymic epithelial tumors by Padda, Sukhmani K, Riess, Jonathan W, Schwartz, Erich J, Tian, Lu, Kohrt, Holbrook E, Neal, Joel W, West, Robert B, Wakelee, Heather A

“…Blockade of the immune checkpoint programmed death receptor ligand-1 (PD-L1)/PD-1 pathway has well-established clinical activity across many tumor types. PD-L1…”
Get more information

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database by Padda, Sukhmani K, Yao, Xiaopan, Antonicelli, Alberto, Riess, Jonathan W, Shang, Yue, Shrager, Joseph B, Korst, Robert, Detterbeck, Frank, Huang, James, Burt, Bryan M, Wakelee, Heather A, Badve, Sunil S

“…Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated…”
Get more information

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer by Hellyer, Jessica A., Stehr, Henning, Das, Millie, Padda, Sukhmani K., Ramchandran, Kavitha, Neal, Joel W., Diehn, Maximilian, Wakelee, Heather A.

“…•KEAP1/NFE2L2/CUL3 co-mutations were observed in 7% of EGFR mutant lung adenocarcinomas.•Patients with co-mutations in KEAP1, NFE2L2, or CUL3 display intrinsic…”
Get full text

Everolimus in the treatment of metastatic thymic epithelial tumors by Hellyer, Jessica A., Ouseph, Madhu M., Padda, Sukhmani K., Wakelee, Heather A.

“…•Everolimus demonstrated efficacy in a real-world cohort of advanced thymic tumors.•Everolimus has expected and manageable toxicities in patients with thymic…”
Get full text

Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy by Padda, Sukhmani K, Burt, Bryan M, Trakul, Nicholas, Wakelee, Heather A

“…Despite cures in early stage (IA–IIB) non-small cell lung cancer (NSCLC), the 5-year survival rate is only 36%–73%. Surgical resection via lobectomy is the…”
Get full text

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging by Alhusaini, Saud, Lanman, Tyler A, Ko, Ryan B, Therkelsen, Kate E, Eyben, Rie Von, Diehn, Maximilian, Soltys, Scott G, Pollom, Erqi L, Chin, Alexander, Vitzthum, Lucas, Wakelee, Heather A, Padda, Sukhmani K, Ramchandran, Kavitha, Loo, Jr, Billy W, Neal, Joel W, Nagpal, Seema

“…The 2-year incidence of brain metastases (BrMs) in stage III non-small lung cell cancer (NSCLC) has been estimated to be around 30%. However, recent clinical…”
Get full text

Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung by Assi, Hussein A., Padda, Sukhmani K.

“…•Neuroendocrine tumors of the lung are a diverse group of diseases.•Small and large cell neuroendocrine carcinomas are high-grade tumors with poor…”
Get full text

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer by Aredo, Jacqueline V, Wakelee, Heather A, Neal, Joel W, Padda, Sukhmani K

“…•Afatinib has limited activity in EGFR-mutant NSCLC after progression on osimertinib•Response to prior osimertinib may be predictive of response to…”
Get full text

Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors by Singhal, Surbhi, Hellyer, Jessica, Ouseph, Madhu M., Wakelee, Heather A., Padda, Sukhmani K.

“…Paraneoplastic autoimmune diseases (ADs) are a hallmark of thymic epithelial tumors (TETs) and affect treatment management in patients with advanced-stage…”
Get full text

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer by Generalova, Olga, Roy, Mohana, Hall, Evan, Shah, Sumit A., Cunanan, Kristen, Fardeen, Touran, Velazquez, Brianna, Chu, Gilbert, Bruzzone, Bianca, Cabot, Anna, Fisher, George A., Srinivas, Sandy, Fan, Alice C., Haraldsdottir, Sigurdis, Wakelee, Heather A., Neal, Joel W., Padda, Sukhmani K., Johnson, Tyler, Heestand, Gregory M., Hsieh, Robert W., Ramchandran, Kavitha

“…Background Patient reported outcomes (PROs) have been associated with improved symptom management and quality of life in patients with cancer. However, the…”
Get full text

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer by Aredo, Jacqueline V., Wakelee, Heather A., Hui, Angela Bik-Yu, Padda, Sukhmani K., Joshi, Nitin D., Guo, H. Henry, Chaudhuri, Aadel, Diehn, Maximilian, Loo, Billy W., Neal, Joel W.

“…•We evaluated induction EGFR TKIs before CRT in patients with stage III EGFR+ NSCLC.•Induction EGFR TKIs resulted in high response rates and recurrence-free…”
Get full text

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC by Hellyer, Jessica A, Padda, Sukhmani K, Diehn, Maximilian, Wakelee, Heather A

“…The KEAP1-NFE2L2 pathway is an important modulator of cell homeostasis. Mutations in this pathway are common in NSCLC and have been associated with enhanced…”
Get more information

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer by Jeong, Youngtae, Hellyer, Jessica A, Stehr, Henning, Hoang, Ngoc T, Niu, Xiaomin, Das, Millie, Padda, Sukhmani K, Ramchandran, Kavitha, Neal, Joel W, Wakelee, Heather, Diehn, Maximilian

“…Activation of NFE2L2 has been linked to chemoresistance in cell line models. Recently, somatic mutations that activate NFE2L2, including mutations in , or have…”
Get full text

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers by Sikic, Branimir I, Lakhani, Nehal, Patnaik, Amita, Shah, Sumit A, Chandana, Sreenivasa R, Rasco, Drew, Colevas, A Dimitrios, O'Rourke, Timothy, Narayanan, Sujata, Papadopoulos, Kyriakos, Fisher, George A, Villalobos, Victor, Prohaska, Susan S, Howard, Maureen, Beeram, Muralidhar, Chao, Mark P, Agoram, Balaji, Chen, James Y, Huang, Jie, Axt, Matthew, Liu, Jie, Volkmer, Jens-Peter, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Supan, Dana, Wakelee, Heather A, Aoki, Rhonda, Pegram, Mark D, Padda, Sukhmani K

“…To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis. Adult…”
Get full text

Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis by Aptekar, Jacob, Jain, Rahul, Korytowsky, Beata, Shafquat, Afrah, Hendershot, Jacob, Talwai, Aniketh, Itzkovich, Yahav, Padda, Sukhmani K.

“…•Data for standard-of-care (SOC) agents are lacking for NSCLC with brain metastases.•We report pooled clinical trial data for docetaxel in KRAS-mutated…”
Get full text

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion by Das, Millie, Padda, Sukhmani K., Weiss, Jared, Owonikoko, Taofeek K.

“…Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available…”
Get full text